AU2014361794B2 - Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof - Google Patents

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof Download PDF

Info

Publication number
AU2014361794B2
AU2014361794B2 AU2014361794A AU2014361794A AU2014361794B2 AU 2014361794 B2 AU2014361794 B2 AU 2014361794B2 AU 2014361794 A AU2014361794 A AU 2014361794A AU 2014361794 A AU2014361794 A AU 2014361794A AU 2014361794 B2 AU2014361794 B2 AU 2014361794B2
Authority
AU
Australia
Prior art keywords
crystalline form
compound
cyclopentyl
dihydroxy
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014361794A
Other languages
English (en)
Other versions
AU2014361794A1 (en
Inventor
Gyorgy Ambrus
Ke Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2014361794A1 publication Critical patent/AU2014361794A1/en
Application granted granted Critical
Publication of AU2014361794B2 publication Critical patent/AU2014361794B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2014361794A 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof Ceased AU2014361794B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
US61/915,575 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (2)

Publication Number Publication Date
AU2014361794A1 AU2014361794A1 (en) 2016-06-16
AU2014361794B2 true AU2014361794B2 (en) 2019-04-04

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014361794A Ceased AU2014361794B2 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Country Status (16)

Country Link
US (2) US9353079B2 (enExample)
EP (1) EP3080096A1 (enExample)
JP (2) JP2016539994A (enExample)
KR (1) KR20160097310A (enExample)
CN (1) CN105814033B (enExample)
AU (1) AU2014361794B2 (enExample)
BR (1) BR112016013594A8 (enExample)
CA (1) CA2933556A1 (enExample)
CL (2) CL2016001448A1 (enExample)
IL (2) IL245917B (enExample)
MX (1) MX2016007717A (enExample)
RU (1) RU2730520C2 (enExample)
SA (1) SA516371307B1 (enExample)
SG (2) SG11201604787SA (enExample)
UA (1) UA121108C2 (enExample)
WO (1) WO2015089475A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10765629B2 (en) * 2017-07-25 2020-09-08 Allergan, Inc. Solid complex, preparations and uses thereof
US20230338194A1 (en) * 2020-01-29 2023-10-26 Kci Licensing, Inc. Mutliple fluid pathway connector with foam supports

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO143741C (no) * 1972-07-13 1981-04-08 Pfizer Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (1998-01-01), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208 *

Also Published As

Publication number Publication date
RU2730520C2 (ru) 2020-08-24
US9353079B2 (en) 2016-05-31
CN105814033A (zh) 2016-07-27
UA121108C2 (uk) 2020-04-10
CA2933556A1 (en) 2015-06-18
AU2014361794A1 (en) 2016-06-16
CN105814033B (zh) 2019-10-25
CL2016001448A1 (es) 2017-03-03
IL245917A0 (en) 2016-08-02
EP3080096A1 (en) 2016-10-19
SG11201604787SA (en) 2016-07-28
US20150166504A1 (en) 2015-06-18
IL283810A (en) 2021-07-29
BR112016013594A8 (pt) 2020-05-19
JP2016539994A (ja) 2016-12-22
US20170087163A1 (en) 2017-03-30
SA516371307B1 (ar) 2018-10-04
KR20160097310A (ko) 2016-08-17
BR112016013594A2 (enExample) 2017-08-08
IL245917B (en) 2021-06-30
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
MX2016007717A (es) 2016-09-09
CL2019000471A1 (es) 2019-07-12
JP2020073513A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
EP1072266B1 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
EP2528908B1 (en) Therapeutic agents for treatment of ocular hypertension
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
HK1227389B (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
GB2076395A (en) Nonaprenylamine derivatives
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
JPWO2006082820A1 (ja) 性器ヘルペス治療剤
HK1178524A (en) Therapeutic agents for treatment of ocular hypertension
HK1178524B (en) Therapeutic agents for treatment of ocular hypertension
WO2013016677A1 (en) N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
KR20010013042A (ko) 경구 흡수도 및 생체이용률이 향상된 ｈｉｖ 프로테아제억제제의 설페이트염

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired